Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864903 | 0.88 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3281524 | 0.87 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL12801190 | 0.86 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL2277132 | 0.86 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL31583988 | 0.86 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL13718678 | 0.84 | GPR119 (0.66) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL18318290 | 0.84 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3156793 | 0.83 | PDE4B (0.51) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL19468677 | 0.83 | KCNH2 (0.45) | PDE4BGPR119PARP1 | |
| SCHEMBL16853782 | 0.83 | KCNH2 (0.45) | PDE4BGPR119PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| EP-3083602-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | PDE4B 1607/4885PDE4D 1411/4885PDE4A 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.